Verona Pharma plc
http://www.veronapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verona Pharma plc
Three Chinese Biotechs Bag Late-Stage VC/PE Funding In February
Evopoint, I-Mab Biopharma (Hangzhou) and MAXVAX extended their funding with series E and C rounds, respectively, in February, amid signs that biotech investor sentiment in China may be recovering.
Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar
Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.
Stock Watch: Fewer Acquisitions Leave Many Behind
The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.
Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast
Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
- Other Names / Subsidiaries
-
- Isis Resources plc
- Rhinopharma Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice